Session (CTI)

This session examines how lifecycle modeling and public perspectives can enhance evidence for health decision-making. Presentations cover life-cycle economic modeling of a tumor-agnostic precision oncology therapy with conditional authorization, public views on modifiers of cost-effectiveness thresholds, and applying a total system value framework to quantify the burden of metabolic liver disease in the US, and assessing the lifecycle value of highly specialized technologies and advanced therapy medicinal products in England.